This technique was initially used to disrupt the CD38 gene in primary NK cells [109], aiming to prevent NK cell cannibalism in combination with daratumumab (anti-CD38) because CD38 is expressed in NK cells, multiple myeloma [110], and acute myeloid leukemia (AML) cells [111]. The gene discussed is CD38; the disease is plasma cell myeloma.